PCSK9 and atherosclerosis: Pharmacological modulation of low-density lipoprotein cholesterol levels via statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors constitutes a key therapeutic strategy for ASCVD risk reduction (3).